Agenus Inc. (NASDAQ:AGEN) is a Lexington, MA-based development-stage company focused on the discovery and development of checkpoint modulators, vaccines and adjuvants for the treatment of cancer.
The company earns revenues primarily through fees received under collaboration and license agreements, which not only provide it with funds in the form of upfront and milestone payments and future royalties, but also validate the company’s proprietary product platform. In Mar 2017, the company undertook certain restructuring activities in order to cut costs and focus on developing key product candidates.
With no approved product in its portfolio yet, investor focus should remain on pipeline updates by the company. The company has three platform technologies for the development of its candidates – Retrocyte Display, SECANT and phage display – each designed to produce quality human antibodies. The company has several early-to-mid stage candidates in its portfolio.
Agenus’ track record has been mixed so far. The company has surpassed estimates twice in the trailing four quarters and missed the same in two other occasions, bringing the average negative surprise to 5.36%.
Currently, Agenus has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Agenus reported narrower-than-expected loss in the first quarter of 2017. Our consensus called for a loss of 32 cents per share, while the company reported a loss of 18 cents.
Revenue: Revenues, however, missed expectations. Agenus posted revenues of $26.6 million, compared to our consensus estimate of $5.22 million.
Cash and Cash Equivalents: Cash, cash equivalents and short-term investments increased $48 million in this quarter sequentially to $124 million as of Mar 31, 2017.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
Agenus Inc. (AGEN): Free Stock Analysis Report
Original post
Zacks Investment Research